Emory University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Emory University sits in the top decile of US sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count).
Emory University: 1,208 sponsored US clinical trials, 208 recruiting.
Emory University sponsors 1,208 registered US clinical trials on ClinicalTrials.gov, 208 of them currently recruiting, and 767 completed. 170 of these trials are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 12 trials.
Top-decile sponsor footprint
Emory University ranks in the top decile of sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
767 of 926 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,208 total, page 17 of 25
Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women
NCT01749566
Protecting Pregnant Women From Infectious Diseases
NCT01761799
Losartan for Sickle Cell Kidney Disease
NCT01989078
DETECT and Retinal Outcomes in Hypertension
NCT01815567
Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients
NCT01792830
A Single Wintertime Dose of Vitamin D3 to Prevent Winter Decline in Vitamin D Status in Healthy Adults
NCT01924910
Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis
NCT01705548
PlasmaKinetic (PK) Button Vaporization Electrode for Treatment of Bladder Tumors
NCT01567462
FACBC Outcomes for Post Prostatectomy
NCT01666808
Anti-1-amino-3-[18F]Fluorocyclobutyl-1-carboxylic Acid (Anti-[18F](FACBC)Positron Emission Tomography (PET-CT) of the Breast
NCT01659645
Properties of Mesenchymal Stem Cells in Lung Transplant
NCT01668576
Vaccine Acceptance in Pregnant Minority Women
NCT01740310
Targeting Reconsolidation to Prevent Return of Fear
NCT01623830
A Phase I Study Evaluating Autologous Bone Marrow Derived Mesenchymal Stromal for Crohn's Disease.
NCT01659762
Postoperative Pain Control Following Vitreoretinal Surgery
NCT01995045
Examination of Differential Valuation of Leisure Items and Attention as Reinforcers in Children With Autism
NCT03152383
Norepinephrine Transporter Availability in PTSD
NCT01799837
Brief Interventions to Create Smoke-Free Home Policies in Low-Income Households
NCT01625468
Potential Use of Indocyanine Green as a Fluorescent Agent for Definition of Surgical Margins in Cancer
NCT01884584
AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia
NCT01655875
Discovering New Biomarkers For Monitoring Disease Progression in Patients With Mucopolysaccharidosis IVA
NCT01733615
Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer
NCT01554969
Point-of-Care Glucose Testing and Insulin Supplementation
NCT01702311
Reperfusion With Cooling in Cerebral Acute Ischemia
NCT01585597
Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease
NCT01565616
Effects of Atomoxetine in Mild Cognitive Impairment
NCT01522404
Effect of Probiotic Supplementation on Immune Function in Healthy Infants
NCT01542320
Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer
NCT01490749
Analysis of Percutaneous Ablations for Cancer Treatment
NCT01563679
Immune Memory After Papillomavirus Vaccination
NCT01505049
Cognitively-Based Compassion Training and Mindfulness Attention Training Program
NCT01592188
A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
NCT01470209
A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT01485835
Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma
NCT01549431
A Double Blind Study Comparing Hyaluronic Acid, Corticosteroid and Placebo During Arthrocentesis for Temporomandibular Joint (TMJ) Dysfunction
NCT01524913
Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
NCT01469572
Stroke Study: Operative Strategies to Reduce Cerebral Embolic Events During Coronary Artery Bypass Surgery
NCT01502683
Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors
NCT01568359
Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme
NCT01435395
Project N-Liten- HIV Prevention for African American Women
NCT01553682
Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus
NCT01498406
Cortisol Suppression and Startle Responses in Posttraumatic Stress Disorder (PTSD)
NCT01477762
Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer
NCT01446458
Investigation of Endothelium in Saphenous Vein Grafts
NCT01510821
Inhibitor Development in Patients With Hemophilia A Undergoing Surgery
NCT01571934
IVIG Treatment for Refractory Immune-Related Adult Epilepsy
NCT01545518
Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
NCT01498588
Study of Axitinib and Temsirolimus in Solid Tumors
NCT01529138
Vitamin D for Enhancing the Immune System in Cystic Fibrosis (DISC Study)
NCT01426256
Management of New-Onset Postoperative Atrial Fibrillation
NCT01395836
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 154 |
| Phase 2 | 190 |
| Phase 3 | 36 |
| Phase 4 | 134 |
Therapeutic Areas
What is open in the Emory University pipeline
208 recruiting of 1,208 indexed (17% open); 767 completed (63%).
Phase mix: 170 late (III/IV) vs 344 early (I/II) (early-phase heavy).
Top condition: Depression (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Emory University: open-pipeline peers nationwide
Peers matched on 1,208 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,208 trials (± recruiting share)
- Northwestern University · 1,209 trials · 15% recruiting
- University of Pittsburgh · 1,238 trials · 13% recruiting
- NYU Langone Health · 1,164 trials · 17% recruiting
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Baylor Research Institute · 17% recruiting · 180 trials
- National Institute on Alcohol Abuse and Alcoholism (NIAAA) · 17% recruiting · 93 trials
- Hunter College of City University of New York · 17% recruiting · 29 trials
- Ochsner Health System · 17% recruiting · 29 trials
Related
What to do with this Emory University page
1,208 registered trials is a research-attention snapshot, not an endorsement of Emory University or any single study.
- 208 of Emory University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition Emory University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Emory University pipeline card: 1,208 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.